Skip to content

Terns Pharmaceuticals, Inc.

CIK 0001831363

← back to feed
Revenue (TTM)
$0
−100.0% YoY FY Apr 2026
Net Income (TTM)
−$94.58M
−8.3% YoY FY Apr 2026
EPS Diluted (TTM)
−$1.07
+8.0% YoY FY Apr 2026
Gross Margin
—
FY Apr 2026
Operating Margin
—
FY Apr 2026
Net Margin
—
FY Apr 2026
Free Cash Flow (TTM)
−$75.19M
FY Apr 2026
Cash
$524.75M
FY Apr 2026
Total Debt
$1.03M
FY Apr 2026
Shares Outstanding
115.52M sh
FY Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings